Orchestra BioMed (OBIO) News Today $2.85 -0.01 (-0.35%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$3.24 +0.40 (+13.86%) As of 04/17/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period What is B. Riley's Estimate for OBIO Q1 Earnings?Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - Equities researchers at B. Riley issued their Q1 2026 earnings per share estimates for shares of Orchestra BioMed in a research note issued to investors on Thursday, April 3rd. B. Riley analyst A. Schock expects that the company will pApril 8, 2025 | marketbeat.comChardan Capital Has Strong Outlook for OBIO FY2025 EarningsOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - Investment analysts at Chardan Capital raised their FY2025 earnings per share (EPS) estimates for shares of Orchestra BioMed in a research note issued on Wednesday, April 2nd. Chardan Capital analyst K. Nakae now forecasts that the comApril 8, 2025 | marketbeat.comOrchestra BioMed (NASDAQ:OBIO) Upgraded by B. Riley to "Strong-Buy" RatingB. Riley raised shares of Orchestra BioMed to a "strong-buy" rating in a research note on Thursday.April 7, 2025 | marketbeat.comOrchestra BioMed (NASDAQ:OBIO) Given New $12.00 Price Target at HC WainwrightHC Wainwright dropped their price target on shares of Orchestra BioMed from $14.00 to $12.00 and set a "buy" rating for the company in a research report on Friday.April 6, 2025 | marketbeat.comOrchestra BioMed price target lowered to $12 from $14 at H.C. WainwrightApril 5, 2025 | markets.businessinsider.com4OBIO : Where Orchestra BioMed Hldgs Stands With AnalystsApril 4, 2025 | benzinga.comOrchestra BioMed's (OBIO) Buy Rating Reiterated at Chardan CapitalChardan Capital reissued a "buy" rating and set a $20.00 price target on shares of Orchestra BioMed in a report on Tuesday.April 4, 2025 | marketbeat.comOrchestra BioMed Reports 2024 Financial Results and Advances Cardiovascular TherapyApril 2, 2025 | msn.comOrchestra BioMed (NASDAQ:OBIO) Posts Earnings Results, Hits EstimatesOrchestra BioMed (NASDAQ:OBIO - Get Free Report) released its earnings results on Monday. The company reported ($0.43) EPS for the quarter, hitting the consensus estimate of ($0.43). Orchestra BioMed had a negative net margin of 2,179.33% and a negative return on equity of 107.04%.April 1, 2025 | marketbeat.comOrchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business UpdateMarch 31, 2025 | globenewswire.comOrchestra BioMed initiated with a Buy at BTIGMarch 21, 2025 | markets.businessinsider.comBTIG Initiates Coverage of Orchestra BioMed Holdings (OBIO) with Buy RecommendationMarch 21, 2025 | msn.comOrchestra BioMed (NASDAQ:OBIO) Coverage Initiated at BTIG ResearchBTIG Research began coverage on Orchestra BioMed in a report on Thursday. They issued a "buy" rating and a $12.00 price objective on the stock.March 21, 2025 | marketbeat.comOrchestra BioMed (OBIO) Projected to Post Earnings on WednesdayOrchestra BioMed (NASDAQ:OBIO) will be releasing earnings before the market opens on Wednesday, March 26, Financial Modeling Prep reports.March 19, 2025 | marketbeat.comOrchestra BioMed's (OBIO) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $14.00 target price on shares of Orchestra BioMed in a research note on Monday.March 10, 2025 | marketbeat.comOrchestra BioMed (NASDAQ:OBIO) Stock Price Up 3.4% - Still a Buy?Orchestra BioMed (NASDAQ:OBIO) Stock Price Up 3.4% - Here's What HappenedMarch 8, 2025 | marketbeat.comOrchestra BioMed to Present at Upcoming Investor ConferencesFebruary 20, 2025 | globenewswire.comOrchestra names Vivek Reddy as chairman of BACKBEAT study steering committeeFebruary 19, 2025 | markets.businessinsider.comOrchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory BoardFebruary 18, 2025 | globenewswire.comBarclays Reaffirms Their Buy Rating on Orchestra BioMed Holdings (OBIO)February 15, 2025 | markets.businessinsider.comOrchestra BioMed (NASDAQ:OBIO) Trading 5.1% Higher - Here's WhyOrchestra BioMed (NASDAQ:OBIO) Trading Up 5.1% - What's Next?February 14, 2025 | marketbeat.comOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Sees Large Decline in Short InterestOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) was the target of a large decline in short interest in January. As of January 31st, there was short interest totalling 474,000 shares, a decline of 35.7% from the January 15th total of 736,700 shares. Based on an average daily volume of 97,000 shares, the short-interest ratio is presently 4.9 days. Approximately 1.8% of the company's shares are short sold.February 14, 2025 | marketbeat.comOrchestra BioMed announces data on atrioventricular interval modulation therapyFebruary 12, 2025 | markets.businessinsider.comOrchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 ConferenceFebruary 12, 2025 | globenewswire.comOrchestra BioMed announces appointment of Cleary to board of directorsFebruary 6, 2025 | markets.businessinsider.comOrchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of DirectorsFebruary 5, 2025 | globenewswire.comOrchestra BioMed Hldgs (NASDAQ:OBIO) Stock Quotes, Forecast and News SummaryJanuary 3, 2025 | benzinga.comBarclays Initiates Coverage of Orchestra BioMed Holdings (OBIO) with Overweight RecommendationJanuary 3, 2025 | msn.comOrchestra BioMed Up 49% After Barclays Starts Coverage With $16 TargetJanuary 2, 2025 | marketwatch.comOrchestra BioMed initiated with an Overweight at BarclaysJanuary 2, 2025 | markets.businessinsider.comOrchestra BioMed (NASDAQ:OBIO) Now Covered by BarclaysBarclays assumed coverage on shares of Orchestra BioMed in a research report on Thursday. They issued an "overweight" rating and a $16.00 target price on the stock.January 2, 2025 | marketbeat.comInsider Buying: Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Insider Acquires 4,000 Shares of StockDecember 27, 2024 | insidertrades.comInsider Buying: Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Insider Purchases 4,000 Shares of StockOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) insider David P. Hochman purchased 4,000 shares of the stock in a transaction dated Monday, December 23rd. The shares were bought at an average price of $4.66 per share, with a total value of $18,640.00. Following the completion of the acquisition, the insider now directly owns 579,498 shares of the company's stock, valued at approximately $2,700,460.68. This represents a 0.70 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.December 26, 2024 | marketbeat.comOrchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) top owners are individual investors with 26% stake, while 22% is held by hedge fundsDecember 25, 2024 | uk.finance.yahoo.comOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Insider David P. Hochman Acquires 5,000 SharesDecember 20, 2024 | insidertrades.comInsider Buying: Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Insider Buys 5,000 Shares of StockOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) insider David P. Hochman acquired 5,000 shares of the company's stock in a transaction dated Wednesday, December 18th. The shares were bought at an average cost of $4.91 per share, with a total value of $24,550.00. Following the purchase, the insider now owns 575,498 shares in the company, valued at approximately $2,825,695.18. The trade was a 0.88 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.December 19, 2024 | marketbeat.comOrchestra BioMed Announces AVIM Therapy Program Presentations at ICI MeetingDecember 10, 2024 | markets.businessinsider.comRTW Investments LP Purchases 2,585,519 Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO)RTW Investments LP grew its position in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) by 46.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,206,159 shares of the company's stock afDecember 5, 2024 | marketbeat.comOrchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | globenewswire.comFY2024 EPS Estimates for Orchestra BioMed Raised by B. RileyOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - Stock analysts at B. Riley upped their FY2024 EPS estimates for Orchestra BioMed in a research note issued on Wednesday, November 13th. B. Riley analyst K. Bauser now forecasts that the company will post earnings of ($1.67) per share fNovember 18, 2024 | marketbeat.comResearch Analysts Offer Predictions for OBIO FY2024 EarningsOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - Equities researchers at Chardan Capital dropped their FY2024 EPS estimates for shares of Orchestra BioMed in a note issued to investors on Wednesday, November 13th. Chardan Capital analyst K. Nakae now expects that the company will posNovember 18, 2024 | marketbeat.comHC Wainwright Has Optimistic Outlook of OBIO FY2024 EarningsOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - Research analysts at HC Wainwright upped their FY2024 earnings estimates for shares of Orchestra BioMed in a report issued on Thursday, November 14th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings peNovember 18, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Orchestra BioMed (NASDAQ:OBIO)HC Wainwright restated a "buy" rating and set a $14.00 price objective on shares of Orchestra BioMed in a research note on Friday.November 15, 2024 | marketbeat.comOrchestra BioMed’s Strong Financial Performance and Strategic Developments Reinforce Buy Rating with $14 Price TargetNovember 15, 2024 | markets.businessinsider.comOrchestra BioMed Holdings: Strategic Financial Developments and Clinical Progress Justify Buy RatingNovember 13, 2024 | markets.businessinsider.comOrchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business UpdateNovember 12, 2024 | globenewswire.comOrchestra BioMed to Present at Jefferies London Healthcare ConferenceNovember 9, 2024 | msn.comOrchestra BioMed Holdings IncNovember 8, 2024 | morningstar.comOrchestra BioMed to Participate in Jefferies London Healthcare ConferenceNovember 7, 2024 | markets.businessinsider.comDavid P. Hochman Purchases 2,500 Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) StockSeptember 27, 2024 | insidertrades.com Get Orchestra BioMed News Delivered to You Automatically Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address OBIO Media Mentions By Week OBIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OBIO News Sentiment▼0.000.54▲Average Medical News Sentiment OBIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OBIO Articles This Week▼01▲OBIO Articles Average Week Get Orchestra BioMed News Delivered to You Automatically Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NPCE News Today DCTH News Today SMLR News Today TCMD News Today CLPT News Today CVRX News Today LUNG News Today ZIMV News Today NNOX News Today SMTI News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OBIO) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orchestra BioMed Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orchestra BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
